1.00 / AMA PRA Category 1 CreditsTM 1.00 / CNE Contact Hours (0.30 pharmacotherapy hour) 1.00 / CE for Pharmacists (0.10 CEUs) 1.00 / CPEU for Registered Dietitians
This activity is jointly provided by Global Education Group and Tarsus Cardio Inc. dba Cardiometabolic Health Congress.
This activity is supported by an educational grant from Novartis Pharmaceuticals Corporation.
Prognosis and treatment of HF patients with preserved ejection fraction (HFpEF) is complicated by diagnostic challenges and complicated pathophysiologies. Compared to HF patients with reduced ejection fraction (HFrEF), HFpEF patients are generally older, more often female, and have increased metabolic comorbidities such as obesity, hypertension, and type 2 diabetes mellitus. These metabolic comorbidities are associated with an increased risk of developing HFpEF, making the increase in metabolic syndrome in the recent decades particularly concerning. The lack of specific therapies for HFpEF have contributed to the increased prevalence and prognosis of the disease, and along with complicated diagnosis and pathophysiologies, contribute to the challenges that clinicians face in managing HFpEF.
To address these clinical practice gaps, expert faculty will focus on the latest evidence-based strategies to manage HFpEF. This 2018 virtual symposium activity will also provide an overview on current and emerging resources and procedures designed to lower hospital readmission rates in HFpEF patients.
US-based healthcare professionals, including primary care clinicians (PCPs), nurse practitioners (NPs), physician assistants (PAs), endocrinologists, diabetologists, pharmacists, cardiologists, lipidologists, and other allied health professionals.
Upon completion of this activity, participants should be able to:
Employ current and emerging approaches and tools to diagnose HFpEF
Identify current treatment guideline recommendations for HFpEF
Recognize current gaps in the guidelines for the treatment of HFpEF
Interpret results from clinical trials for emerging evidence-based therapies for patients with HFpEF
Outline practices and resources aimed to improve hospital readmission rates for patients with HFpEF
Conflict Of Interest Disclosure Policy
Global Education Group (Global) requires instructors, planners, managers and other individuals and their spouse/life partner who are in a position to control the content of this activity to disclose any real or apparent conflict of interest they may have as related to the content of this activity. All identified conflicts of interest are thoroughly vetted by Global for fair balance, scientific objectivity of studies mentioned in the materials or used as the basis for content, and appropriateness of patient care recommendations.
JoAnn Lindenfeld, MD (Chair) Director, Heart Failure and Transplant Professor of Medicine Vanderbilt University School of Medicine Nashville, TN
Dr. Lindenfeld discloses the following: Consultant/Independent Contractor: Abbott, VWare, Relypsa, Novartis, Edwards Grant/Research Support: AstraZeneca
Keith C. Ferdinand, MD, FACC, FAHA Professor of Medicine Tulane University School of Medicine Tulane Heart and Vascular Institute New Orleans, LA
Dr. Ferdinand discloses the following: Consultant/Independent Contractor: Amgen, Sanofi, Novartis, Quantum Genomics, Boehringer Ingelheim
Alanna A. Morris, MD Assistant Professor of Medicine, Division of Cardiology Emory University Clinical Cardiovascular Research Institute Atlanta, GA
Dr. Morris has nothing to disclose.
Accredited Provider Disclosure
The planners and managers reported the following financial relationships or relationships to products or devices they or their spouse/life partner have with commercial interests related to the content of this CME activity:
Ashley Marostica, RN, MSN, has nothing to disclose. Lindsay Borvansky has nothing to disclose. Andrea Funk has nothing to disclose. Amanda Turner has nothing to disclose. Erin Franceschini, MS, has nothing to disclose. Karin McAdams has nothing to disclose.
AMA PRA Category 1 Credit(s)TM
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Global Education Group (Global) and CMHC. Global is accredited by the ACCME to provide continuing medical education for physicians.
Global Education Group designates this virtual activity for a maximum of 1.00 AMA PRA Category 1 CreditsTM . Physicians should claim only the credit commensurate with the extent of their participation in the activity.
CNE Contact Hour(s)
Global Education Group is accredited with distinction as a provider of continuing nursing education by the American Nurses Credentialing Center’s Commission on Accreditation.
This educational activity for 1.00 contact hours is provided by Global Education Group. Nurses should claim only the credit commensurate with the extent of their participation in the activity.
There are 0.30 pharmacotherapy hours available for this activity.
CE for Pharmacists
Global Education Group is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education.
Global Education Group designates this continuing education activity for 1.00 contact hour(s) (0.10 CEUs) of the Accreditation Council for Pharmacy Education. This is a knowledge based activity. Universal Activity Number (UAN): 0530-9999-18-427-H01-P
Global Education Group is a Continuing Professional Education (CPE) Accredited Provider with the Commission on Dietetic Registration (CDR).
CDR Credentialed Practitioners will receive 1.00 Continuing Professional Education units (CPEUs) for completion of this activities / materials.
CPE Provider #GE012
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. Global Education Group (Global) and CMHC do not recommend the use of any agent outside of the labeled indications.
The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of any organization associated with this activity. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed in this activity should not be used by clinicians without evaluation of patient conditions and possible contraindications on dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
To obtain credit, a score of 70% or better on the post-test is required. This activity is offered at no cost to participants. Please proceed with the activity until you have successfully completed all 4 modules, answered all test questions, completed the post-test and evaluation, and have received a digital copy of your credit certificate. Your online certificate will be saved on myCME within your Profile/CME History, which you can access at any time.
For information about the accreditation of this activity, please contact Global Education Group at 303-395-1782 or firstname.lastname@example.org.